Publications

Performance of single-gene noninvasive prenatal testing for autosomal recessive conditions in a general population setting

UNITY Fetal Risk Screen Clinical Validity and Utility

Prenatal Diagnosis

Performance of single-gene noninvasive prenatal testing for autosomal recessive conditions in a general population setting

Performance of single-gene noninvasive prenatal testing for autosomal recessive conditions in a general population setting

UNITY Fetal Risk Screen Clinical Validity and Utility

Prenatal Diagnosis

Performance of single-gene noninvasive prenatal testing for autosomal recessive conditions in a general population setting

Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens

Validation for Red Blood Cell Fetal Antigen NIPT

Scientific Reports

Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens

Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens

Validation for Red Blood Cell Fetal Antigen NIPT

Scientific Reports

Validation of a Non-invasive Prenatal Test for Fetal RhD, C, c, E, Kell and FyA Antigens

Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.

ASCO 2023 E-Publication

Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.

Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.

ASCO 2023 E-Publication

Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.

Methylated ctDNA dynamics correspond with clinical tumor load in metastatic lung cancer patients on therapy

AACR 2023 Poster Session

Methylated ctDNA dynamics correspond with clinical tumor load in metastatic lung cancer patients on therapy

Methylated ctDNA dynamics correspond with clinical tumor load in metastatic lung cancer patients on therapy

AACR 2023 Poster Session

Methylated ctDNA dynamics correspond with clinical tumor load in metastatic lung cancer patients on therapy

Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions

Clinical Validity and Utility for UNITY Carrier Screen with sgNIPT

Genetics in Medicine

Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions

Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions

Clinical Validity and Utility for UNITY Carrier Screen with sgNIPT

Genetics in Medicine

Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions

Validation of single-gene noninvasive prenatal testing for sickle cell disease

Sickle Cell Disease Validation

American Journal of Hematology

Validation of single-gene noninvasive prenatal testing for sickle cell disease

Validation of single-gene noninvasive prenatal testing for sickle cell disease

Sickle Cell Disease Validation

American Journal of Hematology

Validation of single-gene noninvasive prenatal testing for sickle cell disease

Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost

Single-gene NIPT Health Economics

Journal of Medical Economics

Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost

Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost

Single-gene NIPT Health Economics

Journal of Medical Economics

Reflex single-gene non-invasive prenatal testing is associated with markedly better detection of fetuses affected with single-gene recessive disorders at lower cost

Novel methylation-based, tissue-free ctDNA assay accurately quantifies longitudinal tumor burden changes for precision treatment monitoring

Published in AACR 2022 Poster Session

Novel methylation-based, tissue-free ctDNA assay accurately quantifies longitudinal tumor burden changes for precision treatment monitoring

Novel methylation-based, tissue-free ctDNA assay accurately quantifies longitudinal tumor burden changes for precision treatment monitoring

Published in AACR 2022 Poster Session

Novel methylation-based, tissue-free ctDNA assay accurately quantifies longitudinal tumor burden changes for precision treatment monitoring